MD Anderson buys tech from Bellicum; Tarsus’ Lyme disease trial data; Rigel takes Gavreto
22 Feb 2024
VaccinemRNAImmunotherapy
Plus, Ocular Therapeutix’s private placement, LimmaTech Biologics’ shigellosis vaccine data and a collaboration between Hox Therapeutics and Vernalis.
MD Anderson buys tech from Bellicum: The Texas cancer research institution said it has acquired “certain assets” and IP from its Houston neighbor, which last year started a strategic review process. MD Anderson will use the “safety switch” tech in its cell therapies, and the cancer center plans to ink non-exclusive licenses with other academic groups and biopharma companies so they can access it, as well. — Kyle LaHucik
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.